SELLAS Life Sciences soars 240% as Phase 3 AML vaccine trial meets survival goal
Investing.com · · AI-summarised by FinFlash
SELLAS Life Sciences shares surged about 240% after its pivotal Phase 3 REGAL trial of galinpepimut-S, an immunotherapy for acute myeloid leukemia, met its primary overall survival endpoint. The vaccine cut the risk of death by 41% versus best available treatment, with median survival of 24.0 months against 14.7 months, a hazard ratio of 0.59 and p-value of 0.035. No new safety signals emerged. SELLAS plans to seek accelerated FDA filing, targeting a BLA in the first half of 2027.
So What?
A rare clean Phase 3 win for a small-cap biotech could lift sentiment toward cancer-vaccine developers; watch for dilutive financing after the share-price spike.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.